Business
BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization
VANCOUVER, BC / ACCESS Newswire / May 5, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its first national ...
About this update from Bionxt Solutions Inc
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / May 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its first national level patent filing has been accepted by the Eurasian Patent Organization (EAPO). The EAPO has confirmed the Company‘s core patent claims, namely: novelty, inventive step, and industrial applicability.","length":474,"tagName":"p"},{"type":"text","content":"BioNxt's flagship patent filing, which received a positive international examination report from the European Patent Office, reported September 9, 2024, is a comprehensive patent application for sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. This patent family provides numerous proprietary product development and commercialization opportunities, including BioNxt's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for the treatment of multiple sclerosis (MS).","length":546,"tagName":"p"},{"type":"text","content":"The EAPO covers Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, and Turkmenistan. These countries are the members of the Eurasian Patent Convention (EAPC), which provides a single, harmonized patent application process and regulator for the region. The EAPO grants Eurasian patents that are valid in all eight member states.","length":350,"tagName":"p"},{"type":"text","content":"BioNxt continues to advance the nationalization phase of the patent protection process at the European Patent Office and Eurasian Patent Organization, as well as with independent filing nations, such as Australia (AU), Canada (CA), New Zealand (NZ), USA (US), and Japan (JP). Securing nation-level patents around the globe will serve as the foundation for commercial opportunities for the Company's pipeline of sublingual products targeting autoimmune diseases such as multiple sclerosis (MS), myasthenia gravis (MG), lupus nephritis (LN) and rheumatoid arthritis (RA).","length":573,"tagName":"p"},{"type":"text","content":"About BioNxt Solutions Inc.","length":27,"tagName":"p"},{"type":"text","content":"BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screeni...